Page last updated: 2024-11-13
atpenin a5
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
atpenin A5: from Penicillium sp. FO-125; MW C15-H21-N-O5-Cl2 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 54676868 |
CHEMBL ID | 1081615 |
SCHEMBL ID | 1506735 |
SCHEMBL ID | 20472249 |
MeSH ID | M0162588 |
Synonyms (21)
Synonym |
---|
AT5 , |
atpenin a5 |
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethyl-1-oxohexyl]-4-hydroxy-5,6-dimethoxy-2(1h)-pyridinone |
DB04631 |
CHEMBL1081615 |
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethylhexanoyl]-2-hydroxy-5,6-dimethoxy-1h-pyridin-4-one |
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethylhexanoyl]-4-hydroxy-5,6-dimethoxy-1h-pyridin-2-one |
119509-24-9 |
SCHEMBL1506735 |
HB3783 |
c15h21cl2no5 |
DTXSID60152478 |
J-004142 |
SCHEMBL20472249 |
atpenin a5; aa5 |
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethylhexanoyl]-4-hydroxy-5,6-dimethoxypyridin-2(1h)-one |
Q27095367 |
3-[(2s,4s,5r)-5,6-dichloro-2,4-dimethylhexanoyl]-4-hydroxy-5,6-dimethoxy-1,2-dihydropyridin-2-one |
AS-80047 |
CS-0106633 |
HY-126653 |
Research Excerpts
Overview
Atpenin A5 (AA5) is a potent and specific complex II inhibitor. AA5 also activates the mK(ATP) channel and protects against simulated ischemia-reperfusion (IR) injury.
Excerpt | Reference | Relevance |
---|---|---|
"Atpenin A5 (AA5) is a potent and specific complex II inhibitor, and herein we report that AA5 (1 nM) also activates the mK(ATP) channel and protects against simulated ischemia-reperfusion (IR) injury in isolated cardiomyocytes." | ( The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels. Brookes, PS; Wojtovich, AP, 2009) | 1.38 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Pathways (2)
Pathway | Proteins | Compounds |
---|---|---|
anaerobic energy metabolism (invertebrates, mitochondrial) | 13 | 42 |
superpathway of anaerobic energy metabolism (invertebrates) | 16 | 60 |
Bioassays (4)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1202112 | Inhibition of rat liver SQR | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Discovery of N-benzoxazol-5-yl-pyrazole-4-carboxamides as nanomolar SQR inhibitors. |
AID1202111 | Inhibition of bovine heart SQR | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Discovery of N-benzoxazol-5-yl-pyrazole-4-carboxamides as nanomolar SQR inhibitors. |
AID465212 | Inhibition of Septoria nodorum sub-mitochondrial membrane SQR assessed as ubiquinol-dependent reduction of DCIP after 10 mins by spectrophotometry | 2010 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5 | Synthetic atpenin analogs: Potent mitochondrial inhibitors of mammalian and fungal succinate-ubiquinone oxidoreductase. |
AID465211 | Inhibition of bovine heart sub-mitochondrial membrane SQR assessed as ubiquinol-dependent reduction of DCIP after 10 mins by spectrophotometry | 2010 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5 | Synthetic atpenin analogs: Potent mitochondrial inhibitors of mammalian and fungal succinate-ubiquinone oxidoreductase. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (6.25) | 18.7374 |
1990's | 1 (6.25) | 18.2507 |
2000's | 4 (25.00) | 29.6817 |
2010's | 10 (62.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 30.22
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.22) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |